Valuation: Resverlogix Corp.

Market Cap 18.51M 13.26M 11.88M 10.93M 9.9M 1.26B 18.85M 130M 52.31M 662M 49.78M 48.72M 2.09B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 104M 74.75M 66.95M 61.58M 55.8M 7.1B 106M 734M 295M 3.73B 281M 275M 11.77B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.44%
Yield 2024 *
-
Yield 2025 -
1 day-6.25%
1 week-11.76%
1 month-16.67%
3 months-21.05%
6 months-25.00%
Current year-25.00%
1 week 0.08
Extreme 0.075
0.08
1 month 0.08
Extreme 0.075
0.09
Current year 0.08
Extreme 0.075
0.14
1 year 0.08
Extreme 0.075
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap. Importance
6/7/26 Option

Chief Financial Officer

350,000 0.1018%
6/7/26 Option

Chief Financial Officer

-350,000 0.1018%
6/7/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
-6.25%-11.76%-21.05%+7.14% 18.51M
-0.62%-1.87%+42.87%+67.17% 63.77B
-1.54%+1.92%+12.03%+71.60% 56.37B
+0.67%+2.24%+20.36%+102.81% 54.62B
-2.81%-4.31%+23.50%+48.51% 44.06B
-0.33%-1.93%+19.28%+104.26% 42.11B
+0.55%+2.31%+225.14%+840.10% 41B
-3.60%+27.13%+102.09%+90.88% 34.92B
+1.22%-1.44%+14.57%+47.05% 32.82B
+0.89%+20.55%-40.62%+350.50% 24.7B
Average -1.18%+6.79%+39.82%+173.00% 39.44B
Weighted average by Cap. -0.67%+5.44%+47.27%+173.15%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.47M -4.9M -4.51M -4.08M -520M -7.78M -53.76M -21.58M -273M -20.54M -20.1M -862M -7.77M -5.57M -4.99M -4.59M -4.16M -529M -7.91M -54.69M -21.95M -278M -20.89M -20.45M -877M
Net Debt 81.87M 58.68M 52.55M 48.34M 43.8M 5.57B 83.4M 576M 231M 2.93B 220M 216M 9.24B 85.79M 61.49M 55.07M 50.65M 45.9M 5.84B 87.4M 604M 242M 3.07B 231M 226M 9.68B
Projected Income Statement - Annual - Resverlogix Corp.
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
30/10/26 CA$0.0750 -6.25% 42,025
29/10/26 CA$0.0800 +6.67% 20,000
27/10/26 CA$0.0750 -6.25% 3,000